Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors

被引：0

作者：

Hong Chen

Yan Wen

Yun Zeng

Lie Lin

Bihong Sun

Hongqian Zhu

Huiqing He

Xiaotao Wang

Waiyi Zou

Caifeng Zheng

Liling Zheng

Jinxiong Huang

Liping Pang

Jixian Huang

Yuming Zhang

Haiqing Lin

Zelin Liu

Wanshou Zhu

Qiang Wang

Xuan Zhou

Xiaoli Liu

Hong Qu

Zhenfang Liu

Xin Du

Na Xu

机构：

[1] Nanfang Hospital,Department of Hematology

[2] Southern Medical University,Department of Hematology

[3] Yunnan Hematology Hospital,Department of Hematology

[4] First People’ Hospital of Yunnan,Department of Hematology

[5] Affiliated Hospital of Kunming University of Science and Technology,Department of Hematology

[6] First Affiliated Hospital of Kunming Medical University,Department of Hematology

[7] Hematology Research Center of Yunnan Province,Department of Hematology

[8] Hainan General Hospital,Department of Hematology

[9] People’s Hospital of Guangxi Zhuang Autonomous Region,Department of Hematology

[10] Guizhou Provincial People’s Hospital,Department of Hematology

[11] Zhongshan People’s Hospital,Department of Hematology

[12] Guilin Medical University Affiliated Hospital,Department of Hematology

[13] The First Affiliated Hospital,Department of Hematology

[14] Sun Yat-Sen University,Department of Hematology

[15] Shenzhen Bao An People’s Hospital,Department of Hematology

[16] The Second People’s Hospital of Guangdong Province,Department of Hematology

[17] Liuzhou People’s Hospital,Department of Hematology

[18] Peking University Shenzhen Hospital,Department of Hematology

[19] Yue Bei People’s Hospital,Department of Hematology

[20] Shantou University Medical College,Department of Hematology

[21] Affiliated Hospital of Guangdong Medical University,Department of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform

[22] Shenzhen People’s Hospital,undefined

[23] Second Clinical Medical College of Jinan University,undefined

[24] First Affiliated Hospital of Southern University of Science and Technology,undefined

[25] Huazhong University of Science and Technology Union Shenzhen Hospital,undefined

[26] Gaozhou People’s Hospital,undefined

[27] Panyu Central Hospital,undefined

[28] The First Affiliated Hospital of Guangxi Medical University,undefined

[29] The First Affiliated Hospital of Shenzhen University,undefined

[30] Shenzhen Second People’s Hospital,undefined

[31] Shenzhen University School of Medicine,undefined

来源：

Oncology and Therapy | 2024年 / 12卷

关键词：

Chronic myeloid leukemia; Patient; Physician; Quality of life; Discrepancies;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：131 / 145

页数：14

共 50 条

[1] Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors
Chen, Hong
Wen, Yan
Zeng, Yun
Lin, Lie
Sun, Bihong
Zhu, Hongqian
He, Huiqing
Wang, Xiaotao
Zou, Waiyi
Zheng, Caifeng
Zheng, Liling
Huang, Jinxiong
Pang, Liping
Huang, Jixian
Zhang, Yuming
Lin, Haiqing
Liu, Zelin
Zhu, Wanshou
Wang, Qiang
Zhou, Xuan
Liu, Xiaoli
Qu, Hong
Liu, Zhenfang
Du, Xin
Xu, Na
ONCOLOGY AND THERAPY, 2024, 12 (01) : 131 - 145
[2] Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Tolomeo, Manlio
Dieli, Francesco
Gebbia, Nicola
Simoni, Daniele
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (08) : 853 - 863
[3] Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
Wieczorek, Agnieszka
Uharek, Lutz
BIOMARKER INSIGHTS, 2015, 10 : 49 - 54
[4] Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
Haznedaroglu, Ibrahim C.
TURKISH JOURNAL OF HEMATOLOGY, 2013, 30 (03) : 247 - 255
[5] New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Kimura, Shinya
Ashihara, Eishi
Maekawa, Taira
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2006, 7 (05) : 371 - 379
[6] DISCONTINUATION OF TREATMENT WITH TYROSINE KINASE INHIBITORS IN A PATIENT WITH CHRONIC MYELOID LEUKEMIA IN A REGIONAL HOSPITAL
Bobes, Fernandez A. M.
Taboada, Alameda F.
Ramirez, Garcia I.
Fernandez, Bobela R.
Chamorro, Fernandez C.
HAEMATOLOGICA, 2020, 105 : 248 - 248
[7] Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
E Jabbour
M Deininger
A Hochhaus
Leukemia, 2011, 25 : 201 - 210
[8] Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Kyle, Rachel M. A.
Lazo-Langner, Alejandro
Xenocostas, Anargyros
Chin-Yee, Ian H.
Howson-Jan, Kang
Sanford, David
Hsia, Cyrus C.
BLOOD, 2012, 120 (21)
[9] Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia
Sanford, D.
Lazo-Langner, A.
Xenocostas, A.
Chin-Yee, I.
Howson-Jan, K.
Hsia, C.
CURRENT ONCOLOGY, 2014, 21 (02) : E241 - E249
[10] Tyrosine kinase inhibitors in chronic myeloid leukemia
Sawyers, CL
Druker, B
CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1999, 5 (02): : 63 - 69

← 1 2 3 4 5 →